Which company produces ozanimod?

Ozamod (ozanimod) was developed by Celgene (now acquired by Bristol-Myers Squibb), and obtainedin 2020The U.S. Food and Drug Administration (FDA) approved, and the European Commission also approved Ozamod for the treatment of relapsing-remitting multiple sclerosis in adults, and also for the treatment of ulcerative colitis in adults, sold under the trade name Zeposia.

Ozamod is a selective modulator of the S1P receptor and binds to the S1P1R and S1P5R subtypes. Ozamod's mechanism of action is not fully understood, but the drug may reduce the migration of lymphocytes, which often worsens the inflammation associated with multiple sclerosis. The FDA approved Ozamod based on evidence from two clinical trials. Subjects received Ozamod or a control (interferon beta 1a is a product approved for the treatment of relapsing forms of multiple sclerosis) for up to one year or up to two years. Overdose may cause adverse reactions such as drowsiness, fatigue, headache, dizziness, bradyarrhythmias, cardiac conduction defects, hypertension, liver damage and nausea.

The original drug Ozamod has been launched in China, but it has been on the market for a short time and has not been included in the medical insurance. The specific price is not yet clear, and domestic purchase channels are relatively difficult. The price of Ozamod original drug specifications0.92*28 capsules per box listed overseas may be around 19,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There is currently no generic version of Ozamod produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.